Catalyst Event
Bristol-Myers Squibb Co (BMY) · Other
From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)
5/12/2026, 12:00:00 AM
Bristol-Myers Squibb announced a strategic collaboration with Hengrui Pharma on May 12, 2026, to develop 13 early-stage drug programs. BMS will pay $600 million upfront with a potential total deal value of up to $15.2 billion. No market reaction yet; high impact estimated due to the massive scale of the deal ($15.2B), scheduled.
Korean Translation
2026년 5월 12일 항서제약과 13개 신약 프로그램 개발을 위한 전략적 제휴를 발표할 예정임. 아직 시장 반응이 없으나, 152억 달러 규모의 대형 계약으로 높은 시장 영향이 예상됨.
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Giant Biogene Holding Co Ltd (2367) · Other
Ex-dividend date of 2026-06-01 for final and special dividends, scheduled. (Estimated Low impact as dividend is standard).
6/1/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast revenue of 7.52B HKD. Estimated Medium importance as earnings results typically drive significant price movement scheduled.
5/27/2026, 12:00:00 AM